
Nonlinear normative score calculators for NACC UDS3 cognitive tests

John Kornak (UCSF) + many more @ARTFL/LEFFTDS Alzheimer's Disease Centers Program October 20, 2018


NACC UDS of normal controls – Weintraub et al. (2018)

- 3,461 Individuals (Caucasian subset with complete data)
- 29 ADCS
- Outcomes considered Trail Making Test A & B, Letter fluency F & L &, Category fluency – animals & vegetables, Multilingual Naming test total, Number Span longest digit forward & backward, Craft memory – immediate & delay, Benson figure – copy & recall, Montreal Cognitive Assessment (or MoCA), Number Span forward & backward total correct trials
- Assume data approximates distribution of "healthy controls" for each outcome
- *Objective* to detect extremely "bad" scores relative to the control distribution indicative of dementia (focus on FTD)

Basic "normative" Z-scores




Consider a single neuropsychological test -- e.g. Trail Making Test B (TRAILB)



Z-scores for Trail Making Test B score


Divide by SD

Extreme Z-scores (e.g. > 2 or < -2) indicative of cognitive impairment



Allows uniform comparison across scores


But... "normal scores" for younger people not same as for older




Linearly corrected Z-scores

- Linear approach: fit a linear regression to "adjust for" age, sex and education level -- Weintraub et al. (2018)
- To score a new individual 2-stage process:
 - 1. Adjust test score with fitted regression -- i.e. subtract predicted value for the individuals age, sex and education
 - 2. Turn the adjusted test score into a z-score by dividing by linear regression residual standard deviation estimate

Linear regression for age




Linear regression for age – issue 1




FTD often occurs in this lower age range


Issue 1: Can we improve on the straight line fit with a nonlinear fit?




But, is nonlinear regression the right thing to do?



Is nonlinear regression the right thing to do?



Is nonlinear regression the right thing to do?



We do need to be careful when fitting nonlinear models that we do not "overfit"


Present solution: use shape constrained additive models (SCAMs)

- Generalized additive models (GAMs) flexible "smooth" curves to fit data – Hastie & Tibshirani (1986)
- Extend to shape constrained models (SCAMs) -- strictly increasing or decreasing fits – Pya & Wood (2015)
- GAMs/SCAMs use a set of smooth "basis functions" (e.g. P-splines = penalized B-splines) – knitted together with "nice" mathematical properties form a smooth function
- Avoids overfitting by cross-validating checks for a "genuinely improved fit" when adding complexity
- We use SCAM to regress on Age, Sex and Education


SCAM fitted model: TRAILB vs Age



SCAM fitted model: TRAILB vs ED.




Linear regression for age – issue 2




Issue 2: Account for increasing varianceSCAM fitted model: SD vs Age


Estimate standard deviation with age based on an 11 year window (blue line) and fit SCAM




SCAM fitted model: ANIMALS vs Age



SCAM fitted model: ANIMALS vs ED.



SCAM fitted model: ANIMALS SD vs Age



Procedure – look up table for TRAILB

	Α	В	С	D	E
1	NACCAGE	EDUC	SEX	mean.adj	sd.adj
2	40	11	0	119.487918	7.55301009
3	41	11	0	119.500457	8.22482161
4	42	11	0	119.513383	8.89728201
5	43	11	0	119.526919	9.5707555
6	44	11	0	119.54129	10.2456063
7	45	11	0	119.556723	10.9221986
8	46	11	0	119.57344	11.6008966
9	47	11	0	119.591668	12.2820646
10	48	11	0	119.611631	12.9660668
11	49	11	0	119.634357	13.6532756
12	50	11	0	119.674358	14.3442042
13	51	11	0	119.757334	15.0394822
14	52	11	0	119.909324	15.7397425
15	53	11	0	120.156368	16.4456183
16	54	11	0	120.524504	17.1577428
17	55	11	0	121.039773	17.8767489
18	56	11	0	121.728213	18.6032698
19	57	11	0	122.615833	19.3379382
20	58	11	0	123.713499	20.0812027
21	59	11	0	124.992335	20.833029
22	60	11	0	126.417026	21.5933045
23	61	11	0	127.95226	22.3619164

For a new patient:


- 1. Obtain the patient's TRAILB score
- Find the row in the table corresponding to the patients, age, education level and sex (0=M, 1=F) – extract value for mean.adj and sd.adj
- Take the patient's TRAILB score, subtract mean.adj, then divide by sd.adj = patient's z-score

$$z = \frac{x - \mu}{\sigma} = \frac{x - \text{mean. adj}}{\text{sd. adj}}$$

Limitations

- Nonlinear models need more "manipulation" to fit
- Ad hoc SD windowing technique
- Non-normally distributed variation in some variables
- Caucasians only
- Based only on normative individuals

Never lose sight that ideal solution needs distribution of dementia group Z-scores



Optimal Z-score cut-point for classifying dementia depends on the distribution of the dementia Z-scores

Conclusions

- Nonlinear model fitting via SCAMs provides greater improvement in fit (over linear) for the relationship between the predictors (age, sex and education level) and neurocognitive outcomes in the control population.
- Nonlinear modeling thereby leads to adjusted Z-scores that are more representative of the departures from cognitively normal levels relative to their specific age, sex, and education level.

Thanks

In particular, Julie Fields Walter Kremers Sara Farmer Hiroko Dodge Lilah Besser Brad Boeve Adam Boxer Howie Rosen John Kornak^{1*}, Julie Fields², Walter Kremers², Sara Farmer², Hilary W Heuer³, Leah Forsberg², Danielle Brushaber², Amy Rindels², Hiroko Dodge³, Sandra Weintraub⁴, Lilah Besser⁵, Brian Appleby⁶, Yvette Bordelon⁷, Jessica Bove⁸, Patrick Brannelly⁹, Christina Caso¹⁰, Giovanni Coppola⁷, Reilly Dever¹, Christina Dheel², Bradford Dickerson¹¹, Susan Dickinson¹², Sophia Dominguez⁸, Kimiko Domoto-Reilly¹⁰, Kelley Faber¹³, Jessica Ferrall¹⁴, Ann Fishman¹⁵, Jamie Fong¹, Tatiana Foroud¹³, Ralitza Gavrilova², Deb Gearhart², Behnaz Ghazanfari¹⁶, Nupur Ghoshal¹⁷, Jill Goldman¹⁸, Jonathan Graff-Radford², Neill Graff-Radford¹⁹, Ian M. Grant⁴, Murray Grossman⁸, Dana Haley¹⁹, John Hsiao²⁰, Robin Hsiung²¹, Edward D. Huey¹⁸, David Irwin⁸, David Jones², Lynne Jones¹⁷, Kejal Kantarci², Anna Karydas¹, Daniel Kaufer¹⁴, Diana Kerwin²², David Knopman², Ruth Kraft², Joel Kramer¹, Walter Kukull²³, Maria Lapid², Irene Litvan²⁴, Peter Liubenkov¹, Diane Lucente¹¹, Codrin Lungu²⁵, Ian Mackenzie²¹, Miranda Maldonado⁷, Masood Manoochehri¹⁸, Scott McGinnis¹¹, Emily McKinley²⁶, Mario Mendez⁷, Bruce Miller¹, Namita Multani¹⁶, Chiadi Onyike¹⁵, Jaya Padmanabhan¹¹, Alexander Pantelyat¹⁵, Rodney Pearlman²⁷, Len Petrucelli¹⁹, Madeline Potter¹³, Rosa Rademakers¹⁹, Eliana Marisa Ramos⁷, Katherine Rankin¹, Katya Rascovsky⁸, Erik D. Roberson²⁶, Emily Rogalski-Miller⁴, Pheth Sengdy²¹, Les Shaw⁸, Adam M. Staffaroni¹, Margaret Sutherland²⁵, Jeremy Syrjanen², Carmela Tartaglia¹⁶, Nadine Tatton¹², Joanne Taylor¹, Arthur Toga²⁸, John Trojanowski⁸, Ping Wang¹, Bonnie Wong¹¹, Zbigniew Wszolek¹⁹, Brad Boeve², Adam Boxer¹, and Howard Rosen¹, on Behalf of the ARTFL/LEFFTDS Consortium

¹UCSF, San Francisco, CA, USA ² Mayo Clinic Rochester, MN, USA ³ Oregon Health and Science University, OR, USA and University of Michigan, MI, USA ⁴ Northwestern University, Chicago, IL, USA ⁵Florida Atlantic University, Boca Raton, FL, USA ⁶Case Western Reserve University, Cleveland, OH, USA ⁷ Department of Psychiatry, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA ⁸University of Pennsylvania, Philadelphia, PA, USA ⁹Tau Consortium, Rainwater Charitable Foundation, Fort Worth, TX, USA ¹⁰University of Washington, Seattle, WA, USA ¹¹Harvard University/MGH, Boston, MA, USA ¹²Association for Frontotemporal Degeneration, Radnor, PA, USA ¹³National Cell Repository for Alzheimer's Disease (NCRAD), Indiana University, Indianapolis, IN, USA ¹⁴University of North Carolina, Chapel Hill, NC, USA ¹⁵Johns Hopkins University, Baltimore, MD, USA ¹⁶University of Toronto, Toronto, Ontario, Canada ¹⁷Washington University, St. Louis, MO, USA ¹⁸Columbia University, New York, NY, USA ¹⁹Mayo Clinic, Jacksonville, FL, USA ²⁰National Institute on Aging (NIA), Bethesda, MD, USA ²¹University of British Columbia, Vancouver, British Columbia, Canada ²²UTSW, Dallas, TX, USA ²³National Alzheimer Coordinating Center (NACC), University of Washington, Seattle, WA, USA ²⁴UCSD, San Diego, CA, USA ²⁵National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, USA ²⁶University of Alabama at Birmingham, AL, USA ²⁷Bluefield Project to Cure FTD, San Francisco, CA, USA

Funding Acknowledgements

- Study Supported by: U01 AG045390 (PIs Bradley F. Boeve and Howard J. Rosen), U54 NS092089 (PI Adam Boxer, MD) and R01 EB022055 (PI John Kornak, PhD).
- The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA-funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas Wisniewski, MD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG005131 (PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG053760 (PI Henry Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 AG049638 (PI Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), P50 AG047270 (PI Stephen Strittmatter, MD, PhD).